Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
doi: 10.3389/fendo.2026.1694550 Received 28 August 2025 Revised 03 January 2026 Accepted 06 January 2026 Published 27 January 2026 Volume 17 - 2026 Edited by Hossein Neamatzadeh, Shahid Sadoughi University of Medical Sciences and Health Services, Iran Reviewed by Sedigheh Ekraminasab, Shahid Sadoughi University of Medical Sciences and Health Services, Iran Walter Moos, University of California, San Francisco, United States Updates Copyright 2026 Li, Mao, Zhang and Xu
Product quality is top-notch.
OCA downregulates hepatic glucose and lipid metabolism by downregulating SREPB-1c and reducing endogenous bile acid production, via upregulation of FGF19 which then inhibits CYP7A1, the rate-limiting enzyme for the conversion of cholesterol to bile acids.81In addition to these primary metabolic effects, OCA may also decrease portal pressure by increasing iNOS and displaying a wider range of anti-inflammatory and antifibrotic activity.[82], [83] The FXR Ligand Obeticholic Acid in NASH Treatment (FLINT) trial was a randomised, placebo-controlled, phase IIb trial to evaluate the safety and efficacy of OCA in NASH
The catalogue record and literature reference should therefore remain linked but distinct
US$ 25.95
US$ 24.86
US$ 21.32
US$ 21.58
US$ 25.65
US$ 21.82
US$ 29.45
US$ 27.54
US$ 25.72
US$ 23.76
